Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 8/20 | 0.73 |
| ▸ | ESR1 | P03372 | 6/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.67 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | SHBG | P04278 | 1/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.67 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.67 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.67 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656550 | 1.00 | STS (0.73) | STSESR1ESR2NR3C1CYP3A4 | |
| SCHEMBL4572560 | 1.00 | STS (0.73) | STSESR1ESR2NR3C1CYP3A4 | |
| SCHEMBL9148760 | 0.89 | STS (0.73) | STSESR1ESR2NR3C1CYP3A4 | |
| SCHEMBL27885334 | 0.89 | STS (0.73) | STSESR1ESR2NR3C1CYP3A4 | |
| SCHEMBL11799891 | 0.88 | STS (0.69) | STSESR1ESR2NR3C1CYP3A4 | |
| SCHEMBL11796369 | 0.88 | STS (0.69) | STSESR1ESR2NR3C1CYP3A4 | |
| SCHEMBL22181611 | 0.88 | STS (0.71) | STSESR1ESR2NR3C1CYP3A4 | |
| SCHEMBL27047072 | 0.87 | STS (0.71) | STSESR1ESR2NR3C1CYP3A4 | |
| SCHEMBL10600920 | 0.87 | STS (0.70) | STSESR1ESR2NR3C1CYP3A4 | |
| SCHEMBL9150846 | 0.87 | ESR1 (0.72) | STSESR1ESR2NR3C1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6476011-B1 | Methods for introducing an estrogenic compound | STERIX LIMITED (GB) | 2002-11-05 | — | — | US | claimed |
| CN-101565485-B | Method for preparing molecularly imprinted polymers of ethinylestradiol analogue | UNIV NANJING MEDICAL | 2011-01-26 | — | — | CN | disclosed |
| CN-101565485-A | Method for preparing molecularly imprinted polymers of ethinylestradiol analogue | UNIV NANJING MEDICAL (CN) | 2009-10-28 | — | — | CN | disclosed |
| US-6548491-B2 | For therapy of conditions or diseases that are estrogen-dependent, i.e., are estrogen-induced or estrogen-stimulated | SRI INTERNATIONAL | 2003-04-15 | — | — | US | disclosed |
| US-20020032180-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | TANABE MASATO (US) | 2002-03-14 | — | — | US | disclosed |
| EP-1042354-A2 | ESTRONE SULFAMATE INHIBITORS OF ESTRONE SULFATASE, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | SRI INTERNATIONAL (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033858-A9 | ESTRONE SULFAMATE INHIBITORS OF ESTRONE SULFATASE, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | STANFORD RES INST INT (US) | 1999-10-28 | — | — | WO | disclosed |
| WO-1999033858-A2 | ESTRONE SULFAMATE INHIBITORS OF ESTRONE SULFATASE, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | SRI INTERNATIONAL (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032180-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | HSD17B11, ESR2, ESRRA | STS 559/4885ESR1 5/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.